Deep learning-based ranking method for subgroup and predictive biomarker identification in patients.

Area of Science:

• Biomedical Informatics
• Computational Biology
• Pharmacogenomics

Background:

• Identifying patient subgroups with differential treatment responses is crucial for advancing clinical drug development.
• Current deep learning methods often lack clear biological interpretability.
• There is a need for advanced computational approaches to bridge treatment effect heterogeneity and biomarker discovery.

Purpose of the Study:

• To develop a deep learning framework, DeepRAB, for exploring treatment effect heterogeneity.
• To enable predictive biomarker identification for enhanced model interpretability.
• To facilitate the discovery of meaningful biological markers associated with treatment response differences.

Main Methods:

• Introduced DeepRAB, a deep learning framework for individualized treatment rule (ITR) construction.
• Integrated predictive biomarker identification for model interpretability.
• Validated performance using diverse simulated datasets and real-world clinical trial data for adalimumab in hidradenitis suppurativa.

Main Results:

• DeepRAB effectively identified patient subgroups and predictive biomarkers across various simulated data scenarios.
• The framework demonstrated superior performance in biomarker discovery compared to existing methods.
• Application to hidradenitis suppurativa clinical trial data confirmed DeepRAB's utility in identifying key biomarkers and improving prediction.

Conclusions:

• DeepRAB offers a promising deep learning-based approach for patient subgroup identification and predictive biomarker discovery.
• This methodology supports the development of more targeted treatment strategies in clinical research.
• The findings enhance decision-making processes for personalized medicine applications.